A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells

Exclusion Criteria

• •2. Viscosupplementation within 6 months of screening in the targeted joint
• •3. Other Biologic Injection (Platelet Rich Plasma (PRP) or stem cell) within 6 months in the targeted joint
• •4. Surgery in the targeted joint within the past 6 months (either open or scope)
• •5. Planned/anticipated surgery of the targeted joint during study participation
• •6. Systemic or intra-articular injection of corticosteroids in any joint within 3 months before screening (re-screening allowed once this criteria is met)
• •7. Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, congenital sterility or sexual abstinence are considered acceptable forms of birth control. If sexually active, the subject must have been using one of the accepted birth control methods at least one month prior to study entry.
• •8. Part of a vulnerable population per Office for Human Research Protections (OHRP) definition (pregnant women and breast-feeding women, cognitively impaired, prisoners, etc.)
• •9. Unwilling to discontinue the use of Non-Steroidal Anti-Inflammatory (NSAID)s for 7 calendar days prior to the procedure
• •10. Unwilling to discontinue NSAIDS for 5 calendar days after procedure
• •11. Insufficient amount of subcutaneous tissue to allow recovery of at least 100mL of lipoaspirate
• •12. Diagnosed musculoskeletal cancer or any diagnosed cancer, other than musculoskeletal if not on long term remission (e.g. at least 5 years or negative biopsy at last exam), except basal cell carcinoma
• •13. Have received chronic (more than 7 consecutive days) treatment with systemic corticosteroids at a dose equivalent to prednisone ≥ 10 mg/day within 14 days prior to an injection procedure.
• •14. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint. (Nonintervention observational studies are not exclusionary.)
• •15. History of, or ongoing, autoimmune disorder that requires treatment with an immunosuppressive medication
• •16. Subjects who have a documented history or presence of inflammatory arthritis, rheumatoid arthritis, and sepsis in the treatment site
• •17. History of bleeding disorders or inflammatory joint disease
• •18. Inability to hold anti-platelet therapy according to treating provider prior to procedure
• •19. Any medical condition that could preclude participation in the study in the opinion of the investigator
• •20. Active workers' compensation case in progress with the targeted joint
• •21. Daily opioid use for the 3 months prior to screening or anticipated daily use while participating on study
• •22. Psychiatric disorder that may prevent participation in the study in the opinion of the investigators
• •23. A positive screen for human immunodeficiency virus (HIV) by antibodies or nucleic acid test
• •24. Has a known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g. HCV RNA \[qualitative\] is detected)
• •25. Allergy to sodium citrate of any "caine" type of local anesthetic
• •26. Hemoglobin less than 10g/dL at the time of screening
• •27. Leukocytes \<3,000/µL; neutrophils \<1,500/µL; lymphocytes \<800/µL; platelets \<100,000/µL at the time of screening
• •28. Subjects with a known diagnosis of osteoporosis
• •29. Diagnosis of liver disease as defined by alanine aminotransferase (ALT) \>2x the upper limit of age-determined normal (ULN) or total bilirubin \> 1.5x ULN
• •Ankle Cohort:
• •1. Lower leg trauma in a location other than within the ankle
• •2. Arthroscopy or open surgery of the ankle joint within 6 months of screening.
• •3. Extreme obesity, as defined by National Institutes of Health (NIH) Clinical Guidelines Body Mass Index (BMI \> 40)
• •4. Any condition other than OA of the ankle joint which, in the opinion of the investigator, affects their ability to ambulate to a sufficient degree to interfere with the assessment of the safety and treatment effects of the study injection.
• •Hip Cohort:
• •1. Evidence of hip dysplasia (centre edge angle less than 20⁰)
• •2. Previous fracture trauma to the affected hip requiring medical or surgical treatment
• •3. Severe acetabular deformities (e.g. acetabular protrusion, coxa profunda, circumferential labral ossification)
• •4. Infections or skin diseases at target hip joint
• •5. Significant medical co-morbidities (requiring daily assistance for activities of daily living)
• •6. Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
• •7. Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI\>40)
• •8. Femoral head deformity (perthes or AVN)
• •Knee Cohort:
• •1. Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI\>40)
• •2. Clinically apparent tense effusion of the targeted knee
• •3. Significant valgus/varus deformities (+/- 10⁰)
• •Shoulder Cohort:
• •1. Walch B2 glenoid with greater than 10⁰ of retroversion
• •2. Active joint or systemic infection
• •3. Rotator cuff arthropathy
• •4. Significant muscle paralysis
• •5. Charcot's arthropathy
• •Wrist Cohort:
• •1\. Subjects who have a documented diagnosis of active carpal tunnel syndrome